Mehmet Ali Nahit Sendur retweeted
It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC. Potentially NIAGARA has the highest risk population, not all respond to IO and the maintenance phase the most effect- but the OS of gem/cis pembro HR of 1 is concerning. This reflects what we saw in metastatic disease with contradictory results for the big combination trials. Overall EVP looks better and more consistent #ESMO26 @myESMO @Annals_Oncology @OncoAlert
Mehmet Ali Nahit Sendur retweeted
🆙#ESMO26 Rapid Oral II: #LCSM Mets
🔥KANDLELIT-001: Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer (mNSCLC)
🎙️ @nahit_sendur
🔢2680RO
🎯With Pembrolizumab (PD-L1 TPS≥1%): ORR 72%, Median PFS 28.9mo (n=98); TPS≥50% ORR 87%;
🎯Monotherapy ORR 27%; Calderasib+Pembro+Chemo ORR 65%, PFS 15.1mo
☑️NCT05067283
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers
🆙 #ESMO26 Rapid Oral 2: #LCSM Mets
🔥Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer
🎙️ @nahit_sendur
🔢2680RO
☑️NCT05067283
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers
Mehmet Ali Nahit Sendur retweeted
Meme kanserinde erken tanı tedavi başarısını önemli ölçüde artırıyor: Bir farkındalık, bir yaşam
cumhuriyet.com.tr/saglik/mem…
Mehmet Ali Nahit Sendur retweeted
Highlighted Studies at #WCLC26
1️⃣ HARMONi-2
In treatment-naïve, advanced NSCLC with PD-L1 ≥1%, ivonescimab improved PFS (11.1 vs 5.8 months; HR 0.51) and OS (30.8 vs 22.6 months; HR 0.73) compared with pembrolizumab.
This is a genuinely positive trial, but it does not tell the same story for all PD-L1-positive patients. The OS benefit was clear in the ≥50% subgroup, whereas the HR was 0.85 with a confidence interval crossing 1 in the 1–49% subgroup. Moreover, pembrolizumab monotherapy is not the real comparator for most patients in this group; chemo-IO is.
2️⃣ SWOG S1827/MAVERICK
In patients with SCLC who had completed initial treatment and had no brain metastases, MRI surveillance was compared with MRI plus PCI. MRI alone reduced the risk of cognitive failure or death (HR 0.60); grade ≥3 toxicity was 0.8% vs 7.9%. Interim OS and brain metastasis-free survival were not different.
The study does not show that MRI prevents brain metastases more effectively. It shows that adding PCI has so far caused cognitive and serious toxicity without demonstrating a survival benefit. If regular MRI and prompt salvage treatment can be provided, routine PCI is now difficult to justify. Still, it is too early to say that PCI is completely dead before the final OS analysis.
3️⃣ TAISHAN-302
In relapsed SCLC, the B7-H3 ADC Tam-Peli improved OS from 9.4 to 13.3 months versus topotecan (HR 0.46); PFS was 7.4 vs 2.8 months and ORR was 59% vs 10%. Grade ≥3 treatment-related toxicity was also lower.
ARTEMIS-008
In relapsed SCLC, another B7-H3 ADC, Ris-Rez, also outperformed topotecan: OS was 18.5 vs 10.3 months (HR 0.46), PFS was 7.2 vs 3.0 months, and ORR was 58% vs 13%.
Together with TAISHAN-302, this result strongly confirms that B7-H3 is a genuine target in SCLC. However, the median OS figures from the two trials cannot be used to conclude that Ris-Rez is better. The choice between the two ADCs may be determined more by ILD, hematologic toxicity, and ease of administration than by efficacy figures. The efficacy of either agent after tarlatamab maintenance also remains unknown.
5️⃣ EVOKE-03/KEYNOTE-D46
In metastatic NSCLC with PD-L1 ≥50%, sacituzumab govitecan plus pembrolizumab increased ORR compared with pembrolizumab (%56 vs 44%) and numerically prolonged PFS, but the prespecified statistical threshold was not met. OS was 21.5 vs 22.8 months, duration of response was almost identical, and grade ≥3 toxicity was 56% vs 17%.
Adding the ADC shrank tumors in more patients but did not change the natural course of the disease. Considering the similar duration of response, lack of OS benefit, and substantial toxicity, this combination has no place in clinical practice.
Mehmet Ali Nahit Sendur retweeted
Dr. Jie Wang presents results from phase III ARTEMIS-008 trial of risvutatug rezetecan (ris-rez), a B7-H3 antibody drug conjugate (topo-1 payload) vs topotecan in relapsed SCLC at #WCLC26. Included pts with SCLC progressed after 1 line of platinum-based chemotherapy with a 1:1 randomization to ris-rez 8mg/kg q3w vs standard topotecan. Again - 30% of pts had no smoking history - different biology and expect these patterns globally in the coming years.
Mehmet Ali Nahit Sendur retweeted
Replying to @StephenVLiu @IASLC
Happy to see intracranial efficacy as well - icPFS 6.1 vs 4.2 with HR 0.43 favoring tam-peli, icRR 32% vs 3%, icDCR 91% vs 59%.
Safety favors tam-peli with G3+ TRAE 46% vs 75% even with much longer treatment exposure with tam-peli (31m vs 10m). ILD rate with tam-peli 4.9% with most toxicities hematologic in nature. #WCLC26
Mehmet Ali Nahit Sendur retweeted
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (tam-peli, YL201), a B7-H3 antibody drug conjugate (topo-1 payload, DAR 8) vs topotecan in relapsed SCLC at #WCLC26. Included pts with SCLC progressed after 1 line of platinum-based chemotherapy with a 1:1 randomization to tam-peli 2mg/kg q3w vs standard topotecan. Median f/u ~9m and 71 pts in tam-peli arm still on therapy (vs 8 with topotecan). Note that almost 30% of pts with no smoking history - a pattern we are seeing in ES-SCLC as well. Biology shifting...
Mehmet Ali Nahit Sendur retweeted
The OncoAlert #WCLC26 Top 10 Deep Dive! Abstract to be presented Next week
OA09.02 — ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer
ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer
🫁 Single-arm phase 2 study: 127 patients with unresectable stage III NSCLC who had not progressed after platinum-based concurrent chemoradiation received consolidation atezolizumab. Primary endpoint IRF-assessed 12-month PFS.
➡️ 12-month PFS 54.9% (95% CI 46.0–63.7)
➡️ Median OS 38.8 months; median treatment duration 11.0 months
➡️ TRAEs 76.4%; grade 3/4 11.0%; grade 5 in 4 patients (3.1%)
✅ Efficacy consistent with expected anti-PD-L1 outcomes in stage III, with no new safety signals identified.
🎙️ Enriqueta Felip
👥 Luis Corrales · Yun Fan · Emilio Esteban · L.T. Le Quyen · Patricia Iranzo · D. Matias · Mehmet Ali Nahit Şendur · A. Pham · A. Sümbül · Martina Vrankar · G. Zerwes · M. Zhou · S. Chiluveru · A. Greco · J.J. Hsu · P. Zhornikova · Francisco Orlandi
⭐️ These Slides were created based on publicly released #WCLC26 abstracts and to be presented at WCLC! These are not Speaker Slides
@EnriquetaFelip
@nahit_sendur
Pinging our OncoAlert Lung Cancer Faculty
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
@bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
Mehmet Ali Nahit Sendur retweeted
The best science is not only presented.
It is made reachable, safe, and centered on patients.
Grateful to ASCO organizers, staff, patients, advocates, and researchers for moving cancer care forward.
Access, safety, and patient-centered care must remain our compass.
#ASCO26 @ASCO @ASCOPres @OncoAlert @OpenMedicineHQ @AmandaBinDC @ConquerCancerFd
Mehmet Ali Nahit Sendur retweeted
KRAS is no longer undruggable!!!
Pancreatic cancer. 5-year survival under 15%. No targeted therapy for decades. One oral pill just nearly doubled survival in a Phase 3 trial. @OncoAlert
Mehmet Ali Nahit Sendur retweeted
Ask every patient about complementary and alternative medicine (CAM) not to judge, but to protect!
Use of CAM instead of traditional therapies associated with a reduction in survival in breast cancer!
@JAMANetworkOpen @OncoAlert @BreastCancerNow
Mehmet Ali Nahit Sendur retweeted
In patients with stage III dMMR colon cancer:
Adding atezolizumab to mFOLFOX6 significantly improved 3-year disease-free survival (86%🆚76%).
Immunotherapy continues to reshape our approach.
@NEJM @OncoAlert @ONCOassist
Mehmet Ali Nahit Sendur retweeted
sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem
In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert
Mehmet Ali Nahit Sendur retweeted
Perioperative MIBC is entering a new era.
The question is no longer if.
It is which regimen, for which patient.
#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists
3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26
Mehmet Ali Nahit Sendur retweeted
🎯 #IGICC | Managing biomarker-negative metastatic gastric cancer remains challenging.
Dr. Mehmet Ali Nahit Sendur @nahit_sendur reviews first-line doublet chemotherapy standards, the limited role of triplet regimens, and evolving second-line strategies including ramucirumab-based therapy and IO in later lines.
🎥 Watch on #Vumedi: tinyurl.com/yu9wrfj6
#GastricCancer #GIOncology #CancerTreatment
Mehmet Ali Nahit Sendur retweeted
3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26
Mehmet Ali Nahit Sendur retweeted
KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.
Mehmet Ali Nahit Sendur retweeted
Çok önemli, tarihi bir gelişme.
Yıllarca p53 için “ilaçlar için hedeflenemez” denildi.
Kanser gelişiminde çok önemli bir gen!🧬
Belki artık bu cümleyi yeniden düşünme zamanı.
NEJM’de yayımlanan faz 1 çalışmada,TP53 Y220C mutasyonunu hedefleyen rezatapopt ile ümit veren sonuçlar.
Henüz bir dönüm noktası değil.
Ama şunu gösteriyor:
Doğru biyolojiyi anladığımızda,
“imkânsız” dediğimiz kapılar aralanabiliyor.
@NEJM
Mehmet Ali Nahit Sendur retweeted
Erkeklerde kanserlerin %45’i,
Kadınlarda %30’u önlenebilir.
@saglikbakanligi @WHO_Turkiye @WHO @DrTedros #WorldCancerDay
Mehmet Ali Nahit Sendur retweeted
Farelerde kanseri iyileştirmek her hafta manşet olan akademik bir başarıdır, ancak insanın biyolojik labirentinde bu başarıların %90'ı sessizce kaybolur. Barbacid’in talep ettiği 30 milyon €, bir ilacın gerçek dünyaya ulaşması için gereken milyon dolarlık okyanusta sadece küçük bir damladır.
Pazarlama🆚Bilim arasındaki gerilim, onkoloji dünyasında sadece bir iletişim sorunu değil, aynı zamanda etik bir yol ayrımıdır. Bilim, doğası gereği şüpheci ve sabırlıdır; her yeni veriyi en sert testlerden geçirerek doğrulamaya odaklanır. Pazarlama ise bu sürecin içindeki küçük bir başarıyı alıp, onu "mucize" veya "devrim" etiketiyle bir umut ürününe dönüştürerek satışa sunar.
Bizim görevimiz insanlara sadece duymak istediklerini söylemek değil; karmaşayı sadeleştirerek, güven veren bir gerçekliğin huzurunu hissettirmektir.
#pankreas #kanser











































